SCHEMBL20819153

SCHEMBL20819153

N#C[C@@]1(c2ccc3c(N)ncnn23)O[C@](CF)(COCc2ccccc2)[C@@H](OCc2ccccc2)[C@H]1OCc1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ TNK2 Q07912 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22372340 1.00 TNK2 (0.30) TNK2
SCHEMBL22372328 0.85 TNK2 (0.32) TNK2
SCHEMBL31725309 0.80 PDE2A (0.36) TNK2
SCHEMBL23818461 0.79 TNK2 (0.34) TNK2
SCHEMBL25853408 0.79 TNK2 (0.34) TNK2
SCHEMBL20477154 0.79 PDE2A (0.35) —
SCHEMBL17712276 0.79 PDE2A (0.35) —
SCHEMBL12243178 0.79 PDE2A (0.35) —
SCHEMBL20553048 0.79 PDE2A (0.35) —
SCHEMBL29727834 0.79 PDE2A (0.35) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111542531-B Substituted nucleosides, nucleotides and analogues thereof 詹森生物制药有限公司 2024-07-19 — — CN disclosed
US-11773126-B2 Substituted nucleosides, nucleotides and analogs thereof Janssen Pharmaceuticals, Inc. (US) 2023-10-03 — — US disclosed
US-20210395288-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALAOGS THEREOF JANSSSEN BIOPHARMA, INC. (US) 2021-12-23 — — US disclosed
US-11149049-B2 Substituted nucleosides, nucleotides and analogs thereof Janssen Biopharma, Inc. (US) 2021-10-19 — — US disclosed
US-20200277321-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALAOGS THEREOF Janssen Pharmaceuticals, Inc. 2020-09-03 — — US disclosed
EP-3684782-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF Janssen BioPharma, Inc. (US) 2020-07-29 — — EP disclosed
WO-2019053696-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF ALIOS BIOPHARMA, INC. (US) 2019-03-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200277321-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALAOGS THEREOF PNP, RNGTT, NT5C3B TNK2 4052/4885
US-11773126-B2 Substituted nucleosides, nucleotides and analogs thereof PNP, TYMP, SLC29A1 TNK2 2291/4885
US-20210395288-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALAOGS THEREOF PNP, RNGTT, NT5C3B TNK2 4052/4885
US-11149049-B2 Substituted nucleosides, nucleotides and analogs thereof PNP, TYMP, SLC29A1 TNK2 2291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback